Use of cns-homing targeting peptides for treating neurological disorders
AssigneeSilo Pharma, Inc.
InventorEric Weisblum
Life of this patent
Estimating the term…
Abstract
Disclosed herein include methods, compositions, and kits suitable for use in treating, prevent, delaying, or reversing neurological disorders, including dementia and Alzheimer's disease. In some embodiments, the method comprises administering to a subject in a need thereof a therapeutically effective amount of a composition comprising a central nervous system (CNS) homing peptide.
Claims39
A method of treating, preventing, or reversing dementia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a central nervous system (CNS) homing peptide, thereby treating, preventing, or reversing dementia in the subject;
- and wherein the composition does not comprise any additional therapeutic agent.
(canceled)
(canceled)
A method of treating Alzheimer's disease (AD), or delaying or reducing the likelihood of onset of AD, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a central nervous system (CNS) homing peptide, thereby treating AD or delaying or reducing the likelihood of onset of AD in the subject;
- and wherein the composition does not comprise any additional therapeutic agent.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-18. (canceled)
-23. (canceled)
-27. (canceled)
(canceled)
-34. (canceled)
-42. (canceled)
(canceled)
-54. (canceled)
A composition comprising a central nervous system (CNS) homing peptide comprising an amino acid sequence of any one of SEQ ID NOs:
- 1-22, wherein the composition does not comprise any additional therapeutic agent.
-62. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.